Steven W. Pipe, MD

home / authors / steven-w-pipe-md

Director, Pediatric Hemophilia and Coagulation Disorders Program, CS Mott Children's Hospital, and professor, University of Michigan Health

Articles

Steven W. Pipe, MD

Steven W. Pipe, MD, on Data Continuing to Support Etranacogene Dezaparvovec Over SOC in Hemophilia B

December 12th 2023

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed 3-year follow-up data from the HOPE B trial of the approved gene therapy, branded as Hemgenix.

Steven Pipe, MD

Steven Pipe, MD, on Continuing Durability of Etranacogene Dezaparvovec in Hemophilia B

December 17th 2022

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed new follow-up data from the HOPE-B study presented at ASH 2022.

Steven W. Pipe, MD

Steven W. Pipe, MD, on Conducting Further Research in Hemophilia

July 26th 2022

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed current studies evaluating gene therapies in hemophilia.

Steven W. Pipe, MD

Steven W. Pipe, MD, on Challenges in Gene Therapy Trials for Hemophilia

June 24th 2022

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

Steven W. Pipe, MD

Gene Therapy Potential in Hemophilia: Steven W. Pipe, MD

March 15th 2022

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed research with AAV gene therapy in hemophilia.

Steven W. Pipe, MD

Unmet Needs in Hemophilia: Steven W. Pipe, MD

February 22nd 2022

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed the advantages of AAV gene therapies.

Steven W. Pipe, MD

Challenges in Managing Hemophilia: Steven W. Pipe, MD

February 1st 2022

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.

© 2024 MJH Life Sciences

All rights reserved.